J. J. Lee
Chonnam National University
6 Papers
31 Citations
J. J. Lee is an academic researcher from Chonnam National University. The author has contributed to research in topics: Medicine & Survival rate. The author has an hindex of 5, co-authored 5 publications.
Chat about Author
Papers
Telomere length shortening in non-Hodgkin's lymphoma patients undergoing chemotherapy
TL;DR: It is suggested that in NHL patients hematopoietic stem cells lose telomere length during the recovery period from bone marrow suppression after conventional-dose chemotherapy.
69
VEGF as a predictor for response to definitive chemoradiotherapy and COX-2 as a prognosticator for survival in esophageal squamous cell carcinoma.
Mee Sun Yoon,Taek-Keun Nam,J. J. Lee,Sang-Hee Cho,Ju-Young Song,Sung-Ja Ahn,Ik-Joo Chung,Jae-Uk Jeong,Woong-Ki Chung,Byung-Sik Nah +9 more
TL;DR: Results suggest that VEGF might be a predictive factor for treatment response and COX-2 a prognostic factor for OS in patients with ESCC after definitive CCRT.
Molecular prognostic factors in rectal cancer treated by preoperative chemoradiotherapy
TL;DR: It is suggested that the expression of p53 is a potential marker of survival, and may be useful for selecting candidates from rectal cancer patients for more tailored treatment.
Blood pressure and clinical outcomes in patients with diabetes and stable coronary artery disease in THEMIS
Manan Pareek,D. L. Bhatt,Liling Zheng,J. J. Lee,Lawrence A. Leiter,T. Simon,Shamir R. Mehta,R. Harrington,Kim Fox,Anders Himmelmann,Emmanuelle Vidal-Petiot,P. Gabriel Steg +11 more
TL;DR: BP components were independently associated with efficacy and safety outcomes in patients with stable CAD and type 2 diabetes, and no important modification of BP components on the effect of ticagrelor vs. placebo was detected.
Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
Y H Park,J. J. Lee,M H Ryu,S Y Kim,D H Kim,Y R Do,Kyung Hee Lee,S J Oh,Y.-K. Kim,Cheolwon Suh,Dae Seog Heo,B Y Ryoo,J K Kim,H S Song,W S Lee,Hyeoung-Joon Kim,Yung-Jue Bang,S. H. Yang,Sang-Kyun Sohn,Y K Kang +19 more
TL;DR: The addition of rituximab to CHOP combination chemotherapy for DLBCLs showed improved outcomes, particularly in high-risk group according to the IPI, but there was no significant difference in low-risk patients.